Targeting the PI3-kinase pathway in triple-negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) presents significant challenges due to poor prognosis and limited targeted treatments.
• The phosphoinositide 3 (PI3)-kinase/AKT signaling pathway is frequently dysregulated in TNBC, with combined mutations in PIK3CA, AKT1, and phosphatase and tensin homologue (PTEN) observed in 25-30% of advanced cases.
• This pathway dysregulation represents a key oncogenic driver in TNBC.

Purpose of the Study:

• To review the evidence supporting PI3K pathway activation in TNBC.
• To analyze clinical trial data for PI3K, AKT, and mammalian target of rapamycin (mTOR) inhibitors in TNBC treatment.
• To discuss challenges in identifying patients with pathway activation and the potential synergy with immunotherapy.

Main Methods:

• Literature review of studies on PI3K pathway activation in TNBC.
• Analysis of clinical trial outcomes for PI3K/AKT/mTOR inhibitors in TNBC.
• Discussion of diagnostic criteria for pathway activation and future therapeutic strategies.

Main Results:

• Recent randomized trials indicate improved progression-free survival (PFS) with AKT-inhibitors when used alongside first-line chemotherapy in TNBC patients with PI3K pathway genetic aberrations.
• Evidence supports the role of PI3K pathway activation as a therapeutic target in TNBC.

Conclusions:

• Targeted inhibition of the PI3K/AKT pathway, particularly with AKT-inhibitors, offers a promising therapeutic strategy for a subset of TNBC patients.
• Further research is needed to refine patient selection based on pathway activation status and explore combinations with immunotherapy.